Video: New Drug Proves Effective For Renal Cell Cancer Patients
Nivolumab combined with ipilimumab revealed manageable safety, antitumor activity and favorable responses garnering potential long-term benefits.
Diagnosis & Disease Information
Type of Long-term Response to Targeted mRCC Therapy Affects Outcomes
Patients who have a complete response to 2 or more years of anti-VEGF treatment have the best progression-free and overall survival.
Early CRP Response to mRCC Drugs Predicts Survival
Changes in C-reactive protein levels 4 weeks after starting sunitinib or sorafenib treatment are associated with overall and progression-free survival.
RCC Patients May Benefit from Nivolumab After Disease Progression
Nivolumab treatment beyond disease progression results in reductions in tumor burden, study finds.
Recurrence of Low-Risk RCC Uncommon After Surgery
In a study, the 5-year risk of recurrence was 4.8%, 18.1%, and 46.3% for patients with low-, intermediate-, and high-risk disease.
Kidney Cancer Survival Better Among Metformin Users
Patients who used the drug had a 38% lower risk of dying from kidney cancer than non-users, meta-analysis shows.
Targeted Therapies for Advanced RCC Improve Real-World Survival
Overall survival among patients receiving first-line targeted therapy for advanced renal cell carcinoma increased significantly from 2006 to 2012.
Kidney Cancer Linked to Obesity
Study also finds associations between adiposity and 10 other cancers, particularly digestive and hormone-related malignancies.
Broad-spectrum Antibiotics May Reduce Survival in mRCC
The researchers found that patients treated with ABT had decreased progression-free survival compared with those not receiving ATB.
Biologics Combo Shows Promise As First-Line mRCC Therapy
In a phase 2 trial, atezolizumab plus bevacizumab improved PFS versus sunitinib in patients with renal cell carcinoma expressing PD-L1.
- Loading...
Loading...
Next post in Genitourinary Cancers Symposium
Loading... 
Loading...